Viva Biotech announces cumulative buy-back of 19.94 million shares, representing 0.94 % of share capital authorised under 2025 mandate

Bulletin Express05-29

Viva Biotech Holdings disclosed that, as of 29 May 2026, the company has repurchased a total of 19.94 million ordinary shares under the buy-back mandate approved on 12 June 2025. The repurchased shares equal 0.94 % of the issued share capital outstanding on the mandate date. No shares have yet been cancelled, so the issued share count remains unchanged at 2.13 billion.

On 29 May 2026, the most recent trading day covered by the filing, Viva Biotech bought back 820,500 shares on the Hong Kong Stock Exchange at prices ranging between HKD 1.23 and HKD 1.26, for an aggregate consideration of HKD 1.02 million. These shares are intended for cancellation, and a moratorium on new share issues is in effect until 28 June 2026.

Since the start of the current month, the company has executed 15 on-market repurchases, with daily volumes ranging from 493,500 to 4.16 million shares and volume-weighted average prices between HKD 1.25 and HKD 1.57. The mandate allows the company to repurchase up to 212.84 million shares, leaving 192.90 million shares, or 90.58 % of the authorisation, still available.

Apart from the buy-backs, the filing confirms there were no new share issues, transfers of treasury shares or changes in the total number of issued shares during the reporting period. All repurchases were conducted in compliance with Hong Kong Listing Rules and the terms of the shareholder-approved mandate.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121958359?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 18:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121958359","market":"hk","top_or_hot":-1,"title":"Viva Biotech announces cumulative buy-back of 19.94 million shares, representing 0.94 % of share capital authorised under 2025 mandate","media":"Bulletin Express","content":"<p>Viva Biotech Holdings disclosed that, as of 29 May 2026, the company has repurchased a total of 19.94 million ordinary shares under the buy-back mandate approved on 12 June 2025. The repurchased shares equal 0.94 % of the issued share capital outstanding on the mandate date. No shares have yet been cancelled, so the issued share count remains unchanged at 2.13 billion.</p>\n<p>On 29 May 2026, the most recent trading day covered by the filing, Viva Biotech bought back 820,500 shares on the Hong Kong Stock Exchange at prices ranging between HKD 1.23 and HKD 1.26, for an aggregate consideration of HKD 1.02 million. These shares are intended for cancellation, and a moratorium on new share issues is in effect until 28 June 2026.</p>\n<p>Since the start of the current month, the company has executed 15 on-market repurchases, with daily volumes ranging from 493,500 to 4.16 million shares and volume-weighted average prices between HKD 1.25 and HKD 1.57. The mandate allows the company to repurchase up to 212.84 million shares, leaving 192.90 million shares, or 90.58 % of the authorisation, still available.</p>\n<p>Apart from the buy-backs, the filing confirms there were no new share issues, transfers of treasury shares or changes in the total number of issued shares during the reporting period. All repurchases were conducted in compliance with Hong Kong Listing Rules and the terms of the shareholder-approved mandate.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viva Biotech announces cumulative buy-back of 19.94 million shares, representing 0.94 % of share capital authorised under 2025 mandate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViva Biotech announces cumulative buy-back of 19.94 million shares, representing 0.94 % of share capital authorised under 2025 mandate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-29 18:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Viva Biotech Holdings disclosed that, as of 29 May 2026, the company has repurchased a total of 19.94 million ordinary shares under the buy-back mandate approved on 12 June 2025. The repurchased shares equal 0.94 % of the issued share capital outstanding on the mandate date. No shares have yet been cancelled, so the issued share count remains unchanged at 2.13 billion.</p>\n<p>On 29 May 2026, the most recent trading day covered by the filing, Viva Biotech bought back 820,500 shares on the Hong Kong Stock Exchange at prices ranging between HKD 1.23 and HKD 1.26, for an aggregate consideration of HKD 1.02 million. These shares are intended for cancellation, and a moratorium on new share issues is in effect until 28 June 2026.</p>\n<p>Since the start of the current month, the company has executed 15 on-market repurchases, with daily volumes ranging from 493,500 to 4.16 million shares and volume-weighted average prices between HKD 1.25 and HKD 1.57. The mandate allows the company to repurchase up to 212.84 million shares, leaving 192.90 million shares, or 90.58 % of the authorisation, still available.</p>\n<p>Apart from the buy-backs, the filing confirms there were no new share issues, transfers of treasury shares or changes in the total number of issued shares during the reporting period. All repurchases were conducted in compliance with Hong Kong Listing Rules and the terms of the shareholder-approved mandate.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01873","symbol_name":"维亚生物","start_time":0,"source_url":"","article_id":"1121958359","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121958359","pubTimestamp":1780051434,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Viva Biotech Holdings disclosed that, as of 29 May 2026, the company has repurchased a total of 19.94 million ordinary shares under the buy-back mandate approved on 12 June 2025. The repurchased...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01873":"维亚生物"},"translate_title":"维亚生物宣布累计回购1994万股，占2025年授权授权股本的0.94%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01873":1},"content_text":"Viva Biotech Holdings disclosed that, as of 29 May 2026, the company has repurchased a total of 19.94 million ordinary shares under the buy-back mandate approved on 12 June 2025. The repurchased shares equal 0.94 % of the issued share capital outstanding on the mandate date. No shares have yet been cancelled, so the issued share count remains unchanged at 2.13 billion.\nOn 29 May 2026, the most recent trading day covered by the filing, Viva Biotech bought back 820,500 shares on the Hong Kong Stock Exchange at prices ranging between HKD 1.23 and HKD 1.26, for an aggregate consideration of HKD 1.02 million. These shares are intended for cancellation, and a moratorium on new share issues is in effect until 28 June 2026.\nSince the start of the current month, the company has executed 15 on-market repurchases, with daily volumes ranging from 493,500 to 4.16 million shares and volume-weighted average prices between HKD 1.25 and HKD 1.57. The mandate allows the company to repurchase up to 212.84 million shares, leaving 192.90 million shares, or 90.58 % of the authorisation, still available.\nApart from the buy-backs, the filing confirms there were no new share issues, transfers of treasury shares or changes in the total number of issued shares during the reporting period. All repurchases were conducted in compliance with Hong Kong Listing Rules and the terms of the shareholder-approved mandate.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121958359","isCrawlerRequest":true}